OraSure Technologies (OSUR) Proxy filing summary

Executive summary

• Issued materials in response to Altai Capital's campaign to replace two independent directors, clarifying performance, governance, and strategic direction.

• Outlined a focused growth strategy with near-term catalysts, including FDA reviews, product launches, and expected cash flow breakeven entering 2027.

• Highlighted strong momentum in diagnostics, with new products targeting large and growing addressable markets.

• Asserted that now is not the right time for a sale process, emphasizing the company's inflection point and undervalued potential.

Voting matters and shareholder proposals

• Addressed Altai Capital's proposal to replace two independent directors, countering with facts about board performance and engagement.

• Detailed engagement history with Altai, including multiple settlement offers and board refreshment processes.

• Board committed to declassification regardless of Altai's actions.

Board of directors and corporate governance

• Independent directors' stock ownership is more than double the peer median, with robust ownership requirements increased to 4x salary as of January 2025.

• Average tenure of independent directors is less than three years, reflecting ongoing board refreshment.

• Board has significant M&A experience, overseeing over $13bn in transactions.